Answers are grounded in this paper and cite their sources.
Experimental models show β-elemene improves lipid dysfunction in metabolic dysfunction-associated steatohepatitis, highlighting its potential role in treatment.
Metabolic dysfunction-associated steatohepatitis (MASH) is an escalating global health concern with few effective pharmacological treatment options available. β-elemene (ELE) is a natural product derived from Curcuma Rhizoma, which has anti-tumour and anti-inflammatory effects. However, its efficacy and molecular mechanism in MASH have not been elucidated. Two diet-induced MASH models were used to evaluate the therapeutic potential of ELE in vivo. Additionally, RNA sequencing, network pharmacological analysis, and target validation were performed to elucidate the underlying mechanisms. ELE markedly ameliorated lipid dysfunction and the inflammatory response in MASH mice and fatty acids-stimulated hepatocytes. RNA-sequencing analysis indicated that ELE exerted its therapeutic effects through activating the PPARα signalling pathway. Particularly, we found that ELE directly binds to PPARα protein, preventing its degradation via K48-linked polyubiquitination. Notably, the protective effects of ELE on MASH were abolished in the absence of PPARα. Our studies reveal that ELE is a novel stabiliser of PPARα, effectively inhibiting its ubiquitin-mediated degradation in MASH. By preserving the PPARα signalling pathway, ELE enhances lipid homeostasis and relieves the inflammation. Therefore, ELE holds significant potential as a therapeutic candidate for the treatment of MASH.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: